BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22075605)

  • 1. Clinical significance of serum levels of secretory leukocyte protease inhibitor in patients with systemic sclerosis.
    Aozasa N; Asano Y; Akamata K; Noda S; Masui Y; Tamaki Z; Tada Y; Sugaya M; Kadono T; Sato S
    Mod Rheumatol; 2012 Aug; 22(4):576-83. PubMed ID: 22075605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis.
    Kodera M; Hasegawa M; Komura K; Yanaba K; Takehara K; Sato S
    Arthritis Rheum; 2005 Sep; 52(9):2889-96. PubMed ID: 16142750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum alarm antiproteases in systemic sclerosis patients.
    Olewicz-Gawlik A; Trzybulska D; Graniczna K; Kuznar-Kaminska B; Katulska K; Batura-Gabryel H; Frydrychowicz M; Danczak-Pazdrowska A; Mozer-Lisewska I
    Hum Immunol; 2017 Sep; 78(9):559-564. PubMed ID: 28606626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated serum concentrations of triggering receptor expressed on myeloid cells-1 in diffuse cutaneous systemic sclerosis: association with severity of pulmonary fibrosis.
    Tomita H; Ogawa F; Hara T; Yanaba K; Iwata Y; Muroi E; Yoshizaki A; Komura K; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
    J Rheumatol; 2010 Apr; 37(4):787-91. PubMed ID: 20156945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of serum growth differentiation factor-15 levels in systemic sclerosis: association with disease severity.
    Yanaba K; Asano Y; Tada Y; Sugaya M; Kadono T; Sato S
    Mod Rheumatol; 2012 Sep; 22(5):668-75. PubMed ID: 22160844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of impairment in lung diffusing capacity in patients with systemic sclerosis.
    Guarnieri G; Zanatta E; Mason P; Scarpa MC; Pigatto E; Maestrelli P; Cozzi F
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S80-6. PubMed ID: 25897784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance capacity evaluated using the 6-minute walk test: 5-year results in patients with diffuse systemic sclerosis and initial interstitial lung disease.
    Rizzi M; Sarzi-Puttini P; Airoldi A; Antivalle M; Battellino M; Atzeni F
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S142-7. PubMed ID: 26339893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of organ involvement in systemic sclerosis by serum biomarkers and peripheral endothelial function.
    Kawashiri SY; Nishino A; Igawa T; Takatani A; Shimizu T; Umeda M; Fukui S; Okada A; Suzuki T; Koga T; Iwamoto N; Ichinose K; Tamai M; Nakashima M; Mizokami A; Matsuoka N; Migita K; Ogawa F; Ikeda S; Maemura K; Nakamura H; Origuchi T; Maeda T; Kawakami A
    Clin Exp Rheumatol; 2018; 36 Suppl 113(4):102-108. PubMed ID: 29652651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-17 and interleukin-23: importance in the pathogenesis of lung impairment in patients with systemic sclerosis.
    Olewicz-Gawlik A; Danczak-Pazdrowska A; Kuznar-Kaminska B; Gornowicz-Porowska J; Katulska K; Trzybulska D; Batura-Gabryel H; Silny W; Poplawski D; Hrycaj P
    Int J Rheum Dis; 2014 Jul; 17(6):664-70. PubMed ID: 24467649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased serum pentraxin 3 in patients with systemic sclerosis.
    Iwata Y; Yoshizaki A; Ogawa F; Komura K; Hara T; Muroi E; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Takehara K; Sato S
    J Rheumatol; 2009 May; 36(5):976-83. PubMed ID: 19273457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum resistin levels: a possible correlation with pulmonary vascular involvement in patients with systemic sclerosis.
    Masui Y; Asano Y; Akamata K; Aozasa N; Noda S; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sumida H; Kuwano Y; Yanaba K; Tada Y; Sugaya M; Sato S; Kadono T
    Rheumatol Int; 2014 Aug; 34(8):1165-70. PubMed ID: 24141536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased production of soluble inducible costimulator in patients with diffuse cutaneous systemic sclerosis.
    Yanaba K; Asano Y; Noda S; Akamata K; Aozasa N; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sumida H; Kuwano Y; Tada Y; Sugaya M; Kadono T; Sato S
    Arch Dermatol Res; 2013 Jan; 305(1):17-23. PubMed ID: 23053221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum omentin levels: A possible contribution to vascular involvement in patients with systemic sclerosis.
    Miura S; Asano Y; Saigusa R; Yamashita T; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Tamaki Z; Tada Y; Sugaya M; Sato S; Kadono T
    J Dermatol; 2015 May; 42(5):461-6. PubMed ID: 25766303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum concentration of surfactant protein D in patients with systemic sclerosis: The potential marker of the interstitial lung disease severity.
    Grosicka A; Manasar A; Kucharz EJ; Kotyla PJ
    Best Pract Res Clin Rheumatol; 2018 Aug; 32(4):541-549. PubMed ID: 31174823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease.
    Launay D; Mouthon L; Hachulla E; Pagnoux C; de Groote P; Remy-Jardin M; Matran R; Lambert M; Queyrel V; Morell-Dubois S; Guillevin L; Hatron PY
    J Rheumatol; 2007 May; 34(5):1005-11. PubMed ID: 17444586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels, tissue expression and cellular secretion of macrophage migration inhibitory factor in limited and diffuse systemic sclerosis.
    Corallo C; Paulesu L; Cutolo M; Ietta F; Carotenuto C; Mannelli C; Romagnoli R; Nuti R; Giordano N
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S98-105. PubMed ID: 26005773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
    Asano Y; Ihn H; Yamane K; Yazawa N; Kubo M; Fujimoto M; Tamaki K
    Arthritis Rheum; 2001 Jun; 44(6):1363-9. PubMed ID: 11407696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group.
    Muangchan C; Harding S; Khimdas S; Bonner A; ; Baron M; Pope J
    Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1405-14. PubMed ID: 22556030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Free light chains of immunoglobulins in patients with systemic sclerosis: correlations with lung involvement and inflammatory milieu.
    Bosello S; Basile U; De Lorenzis E; Gulli F; Canestrari G; Napodano C; Parisi F; Pocino K; Di Mario C; Tolusso B; Ferraccioli G; Gremese E
    J Clin Pathol; 2018 Jul; 71(7):620-625. PubMed ID: 29447111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Surfactant proteins-A and D as important serum markers for interstitial lung disease in patients with polymyositis or dermatomyositis].
    Chen F; Shu XM; Wang DX; Xie Y; Wang GC
    Zhonghua Yi Xue Za Zhi; 2012 Aug; 92(31):2182-5. PubMed ID: 23158422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.